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Abstract
Background: The Binge Eating Genetics Initiative (BEGIN) is a multipronged investigation examining the interplay
of genomic, gut microbiota, and behavioral factors in bulimia nervosa and binge-eating disorder.
Methods: 1000 individuals who meet current diagnostic criteria for bulimia nervosa or binge-eating disorder are
being recruited to collect saliva samples for genotyping, fecal sampling for microbiota characterization, and
recording of 30 days of passive data and behavioral phenotyping related to eating disorders using the app Recovery
Record adapted for the Apple Watch.
Discussion: BEGIN examines the interplay of genomic, gut microbiota, and behavioral factors to explore etiology
and develop predictors of risk, course of illness, and response to treatment in bulimia nervosa and binge-eating
disorder. We will optimize the richness and longitudinal structure of deep passive and active phenotypic data to lay
the foundation for a personalized precision medicine approach enabling just-in-time interventions that will allow
individuals to disrupt eating disorder behaviors in real time before they occur.
Trial registration: The ClinicalTrials.gov identifier is NCT04162574. November 14, 2019, Retrospectively Registered.
Keywords: Binge eating, Eating disorders, Wearable technology, Mobile application, Genetics, Microbiome
Background
Bulimia nervosa (BN: lifetime prevalence of 1.5% in
women and 0.5% in men) and binge-eating disorder
(BED: lifetime prevalence of 3.5% in women and 2% in
men) are common debilitating eating disorders [1]. BN
is marked by uncontrollable eating episodes coupled
with compensatory behaviors, whereas BED includes
similarly defined binge episodes only in the absence of
regular compensatory behaviors. Both disorders are
highly heritable (41–82% [2–7]), carry high psychiatric
and somatic comorbidity, and have high medication and
healthcare utilization, whether or not comorbid obesity
is present [8–11]. Suicide risk is significantly elevated in
both disorders [12].
The Binge Eating Genetics Initiative (BEGIN) is a mul-
tipronged research study that 1) examines the interplay
of genomic, gut microbiota, and behavioral factors to ex-
plore etiology and develop predictors of risk, course of
illness, and response to treatment in BN and BED; and
2) optimizes the richness and longitudinal structure of
deep passive and active phenotypic data to lay the foun-
dation for a personalized precision medicine approach
enabling just-in-time interventions that will allow indi-
viduals to disrupt eating disorder behaviors in real time
before they occur.
Genomics
Despite their prevalence and the attendant personal and
social costs, research into the genetic underpinnings of
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BN and BED is essentially absent. BEGIN represents the
first contribution to a global effort to amass an adequate
sample size to conduct a genome-wide association study
of BN and BED in collaboration with the Eating Disor-
ders Working Group of the Psychiatric Genomics Con-
sortium (PGC-ED). The PGC-ED has rapidly advanced
the study of the genomics of anorexia nervosa [13, 14]
identifying eight significant loci and reporting a panel of
genetic correlations suggesting that anorexia nervosa
may have both psychiatric and metabolic etiological un-
derpinnings. BEGIN will further the mission of the
PGC-ED by launching a parallel investigation into BN
and BED.
Intestinal microbiota
Inspired by reports of associations between enteric mi-
crobes, host metabolism, and host behavior [15–17]
along with reported differences between gut microbiota
composition from patients with anorexia nervosa and
healthy individuals [18–25], we have incorporated the
study of the intestinal microbiota into BEGIN. In
addition to characterizing the biogeography of the hu-
man microbiome (cumulative genomes of the micro-
biota) of BEGIN participants, our analyses will identify
associations between genes and microbial composition
in BN/BED. The intention is to better understand the
biological mechanisms of these illnesses in an effort to
help identify potential drug targets and opportunities for
novel interventions.
Deep phenotyping
We are capturing real-time longitudinal digital pheno-
typic data on individuals with BN/BED that reflect the
true complexity of human behavior. Using Apple Watch
and iPhone devices, we are collecting active data on
binge-eating, purging, nutrition, mood, and cognitions
with a widely-used cognitive-behavioral based eating dis-
order app Recovery Record [26] and passive sensor data
via native applications collected over a 30-day period.
We will combine active Recovery Record-based measures
and passively collected, continuous, sensor-based mea-
surements of autonomic nervous system (ANS) activity
and actigraphy to characterize patterns of when and
where individuals are more/less likely to binge and/or
purge in their daily lives. Finally, across and within indi-
viduals, we will identify low-risk and high-risk passive
data patterns that will facilitate the prediction of transi-
tions to high risk states signaling impending binge or
purge episodes (time-stamped by active app monitoring).
This work has the potential to transform the standard of
care for BN and BED by transcending current cognitive-
behavioral therapy (CBT) approaches typically
dependent on retrospective self-report and giving
patients a tailored tool that will help them intervene
when they need help the most.
Method
Specific aims genomics and microbiota
In 1000 individuals with BN/BED, we will,
Aim 1: Contribute genomic data to the next genome-
wide association study (GWAS) conducted by the Eating
Disorders Working Group of the Psychiatric Genomics
Consortium (PGC-ED) of BN/BED.
Aim 2: Comprehensively characterize the biogeog-
raphy of the human microbiome using high-throughput
sequencing of the microbial 16S rRNA gene and shallow
shotgun sequencing.
Aim 3: Employ novel and develop new analytic
methods to integrate GWAS, gut microbiota, and
phenotypic data that will result in predictive algorithms
that index risk, course of illness, severity, disordered eat-
ing episodes, and treatment response.
Specific aims digital longitudinal phenotyping
Aim 1: Conduct longitudinal deep phenotyping of 1000
individuals with BN/BED using Recovery Record and
Apple Watch.
Aim 2: Predict the occurrence of binge eating and pur-
ging (vomiting) episodes in individuals with BN/BED
using passive sensor data.
Aim 3: Test theoretically derived regulatory models of
binge eating and purging behaviors as reflected in differ-
ences in temporal patterns.
Aim 4: Refine our capacity to predict binge and purge
episodes by augmenting passive data with contextual fac-
tors collected by Recovery Record.
Participants
We are recruiting 1000 individuals with BN or BED.
Inclusion criteria
1) Currently meets Diagnostic and Statistical Manual
for Mental Disorders -5th Edition (DSM-5 [27])
criteria for BN or BED (confirmed via validated
questionnaire in screening instrument—see
Measures)
2) Resident of US
3) All sexes
4) Age 18–45 years
5) Reads, speaks English
6) Existing iPhone user with iPhone 5 or later
7) Willing/able to wear Apple Watch for entire study
period
8) Willing/able to use Recovery Record for the entire
study period
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9) Provides informed consent to have activity and self-
reported Recovery Record data harvested
10) Ambulatory.
Exclusion criteria
1) Currently pregnant or breastfeeding
2) Bariatric surgery due to the impact on eating
patterns, including the following: (Roux-en-Y
gastric bypass, laparoscopic adjustable gastric
banding, sleeve gastrectomy, duodenal switch with
biliopancreatic diversion, gastric balloon,
AspireAssist)
3) Current use of hormone therapy
4) Inpatient treatment or hospitalization for eating
disorders in the 2-weeks prior to study enrollment
5) Suicidality at screening
6) Antibiotic or probiotic use in the past 30 days
(related to fecal sampling).
Recruitment
We are recruiting cases nationally from diverse geo-
graphical, socioeconomic, racial, and ethnic backgrounds
via Recovery Record, social media and National Eating
Disorders Association. Specifically, we launch tweets and
Facebook posts that direct potential participants to the
BEGIN url https://www.med.unc.edu/psych/eatingdisor-
ders/research/participate-in-a-study/begin-study/ where
they can take a preliminary screen. In addition, Recovery
Record pushes notifications about BEGIN to users. Re-
cruitment flow is detailed in Fig. 1.
Procedure
Informed consent is obtained digitally via the Recovery
Record app. Participants complete an eating disorders
diagnostic questionnaire. Those who screen case positive
and meet all inclusion criteria are offered the opportun-
ity to participate in the full study (with a second digital
informed consent). All responses to questionnaires are
encrypted and sent to a secure research server at the
UNC Sheps Center for Health Services Research using
secure transfer methodologies, who compile and house
the data in servers specifically designed for Protected
Health Information. Data are de-identified (Sheps Center
maintains the key to match records). Study data from
Recovery Record and the Apple Watch are maintained by
Fig. 1 BEGIN study recruitment and sampling flow
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Recovery Record and only includes passive and active
sources necessary for analyses, minimizing exposure of
protected health information. To ensure that a high level
of security is maintained, data transfer from Recovery
Record occurs with end-to-end encryption and authenti-
cation protocols. Records are only identified with a sec-
ond study number that can be linked using the data
from the Sheps Center. Eligible participants are mailed a
package containing a description of the study, saliva col-
lection kit, microbiome collection kit, and an Apple
Watch. Saliva kits are returned directly to RUCDR Infin-
ite Biologics where they are stored awaiting DNA extrac-
tion and genotyping. In Phase 1, participants returned
microbiome kits to uBiome for sequencing; in Phase 2,
kits are returned to the Carroll lab. Barcodes ensure ac-
curate identification and coordination with phenotypic
data. After enrollment and completion of the baseline
survey, participants use the Apple Watches and Recovery
Record for 30 days and complete midpoint and end-of-
study surveys at 14 days and 30 days post-enrollment, re-
spectively, to track progress of eating disorder pathology,
including binge eating and purging behaviors.
Measures
Deep Phenotyping
Using the Recovery Record app and the Apple Watch
over a 30-day period for each individual, we conduct ac-
tive and passive data capture to fully characterize disor-
dered eating behaviors, physical activity, nutrition,
gastrointestinal distress, sleep, and heart rate. This gen-
erates exceptional data to enable deep characterization
of the course of BN/BED. We expect that the likelihood
of an event (i.e., binge/purge) will decrease over the
course of 30-days and build this expectation into our
statistical models. We further expect that although the
likelihood of events will change over time, the dynamics
of the events will not. These data can be broken down
into four categories. First, self-report questionnaires are
collected consisting of scales well established to relate to
BN and BED (see Self-report questionnaires), measured
prior to enrollment or three times across the study. Sec-
ond, stratified sample intensive measurements consisting
of daily mood and meal records are measured 6 times
daily. Third, event contingent intensive measurements
ask participants to log binge and purge episodes. Finally,
continuous passive data collection captures real-time
physiological and movement data. These different data
will be integrated through multilevel modeling and sys-
tems continuous time modeling procedures [28, 29].
Active data collection
Self-report questionnaires All BEGIN study partici-
pants are screened for eligibility and consented using the
Recovery Record iPhone app, which is free for users to
download and is HIPAA compliant (www.recoveryre-
cord.com). All questionnaires are completed from within
the Recovery Record app.
ED100K [30] The ED100K questionnaire is a self-
report, eating disorders assessment based on the Struc-
tured Clinical Interview for DSM-5, Eating Disorders
Module, administered prior to enrollment. Items assess
DSM-5 criteria for anorexia nervosa, BN, BED, and
other specified feeding and eating disorders. The
ED100K-v1 was found to be a valid measure of eating
disorders and behaviors [30]. Positive predictive values
indicating that among those who had a positive screen-
ing test, anorexia nervosa Criterion B, Criterion C, and
binge eating ranged from 88 to 100%. Among women
who had a negative screen, the probability of not having
these criteria or behaviors ranged from 72 to 100%. The
correlation between questionnaire and interview for low-
est illness-related BMI was r = 0.91.
Eating disorders examination questionnaire (EDE-Q)
[31] The EDE-Q is a widely used, validated question-
naire capturing eating disorders pathology, including the
frequency and severity of binge episodes. The EDE-Q is
administered at baseline, midpoint, and endpoint of the
30-day period.
The Patient Health Questionnaire (PHQ-9) [32] Is a
9-item, self-administered version of the PRIME-MD
diagnostic instrument for common mental disorders.
The nine items are based on the nine DSM-IV criteria
for major depressive disorder and are scored as “0” (not
at all) to “3” (nearly every day). The PHQ-9 has been
found to be a reliable and valid measure of depression
severity. The PHQ-9 is administered at baseline, mid-
point, and endpoint of the 30-day period.
The Generalized Anxiety Disorder 7 (GAD-7) [33] Is
a 7-item, self-report questionnaire to screen for general-
ized anxiety disorder. Each symptom is scored on a 3-
point scale: “not at all” (0), “several days” (1), or “more
than half the days” (2). Items are then summed to create
a symptom severity score. The GAD-7 is a reliable and
valid measure of anxiety. The GAD-7 is administered at
baseline, midpoint, and endpoint of the 30-day period.
ADHD self-report scale (ASRS) [34] Is an 18-item
questionnaire that assess symptoms associated with
attention-deficit/hyperactivity disorder. Items are scored
on a 5-point scale. The assessment has high internal
consistency and validity [35]. The ASRS is administered
at baseline.
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Rome III [36] To assess adult GI symptoms of the
stomach and intestines, the relevant section (items 17–
67) of the ROME III is administered at baseline.
Stratified sampled intensive measurements
Daily mood and meal records These data are collected
inside the Recovery Record iPhone app that primarily tar-
gets adherence to meal monitoring tasks. Participants
are prompted with a push notification six times per day
corresponding to meal and snack times to complete an
evidence-based CBT-style question set (what was eaten,
with whom, where, and what behaviors were used) in
addition to optional symptom-focused questions includ-
ing current emotional state, urges to engage in eating
disorder behaviors, sleeping patterns, hunger levels,
gastrointestinal problems, and intrusive thoughts.
Event contingent intensive measurements
Binge and purge records Participants are instructed to
launch the Recovery Record Apple Watch app if they
have experienced a binge or purge episode (Fig. 2). Ac-
tion buttons are used to quickly identify the relevant
symptom and how long ago it occurred, with response
options in five-minute increments ranging from “Right
now” to “30 mins ago”. If an urge to engage in a behav-
ior is identified, participants are additionally asked to
rate the urge strength with response options: “Not at
all”, “Slight”, “Moderate”, “Strong”, and “Overbearing”.
Actively monitored mood, meal, binge and purge re-
cords and their respective timestamps are collected on
the Recovery Record platform and shared with the
research team via encrypted authenticated TLS. Eco-
logical momentary assessment-based logging has shown
moderate to strong concordance with retrospective self-
report of binge eating and purging [37].
Continuous passive data collection
Apple watch The number and timing of the steps
(physical activity) as well as 5-min epoch heart rate are
passively collected for each study participant using the
Apple Watch and harvested by the Recovery Record app
using Apple’s Application Program Interface (API). The
Apple Watch activates the sensor approximately every 5
min to record heart rate based on 100 Hz using photo
plethysmography. Built in signal processing algorithms
are used to aggregate measurements to approximately 5-
min intervals, a rate consistent with current methodo-
logical guidelines (e.g., Berntson [38]). To minimize data
loss, these variables are uploaded to the Recovery Record
server each time the Recovery Record app is opened on
the iPhone while the Apple Watch is nearby, or at least
once per day.
Biological sampling
Saliva sampling and genotyping Saliva samples are col-
lected with RUCDR Infinite Biologics saliva collection
kits. GWAS profiling will be performed together with
additional samples collected by the PGC-ED using the
optimal platform at the time of genotyping, most likely a
version of the Illumina Global Screening Array (GSA).
Fig. 2 Recovery Record for Apple Watch screen examples. Image Action Buttons include icons created and owned by Recovery Record, Inc. (J.
Tregarthen, author, CEO). Image Distractions features Relaxed Corgi GIF uploaded by GIPHY, 27 June 2016, https://giphy.com/gifs/7Y66VN3rtkPtu.
These images were made available for the purpose of this research per our subcontract agreement with Recovery Record, Inc. (J. Tregarthen,
Principal Investigator and author). The image titled Distractions features Relaxed Corgi GIF uploaded by GIPHY, 27 June. 2016, https://giphy.com/
gifs/7Y66VN3rtkPtu. The GIF was accessed utilizing the Recovery Record, Inc. GIPHY account and made available under a license agreement
between Recovery Record, Inc. and GIPHY
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Fecal sampling and sequencing In Phase 1, as recipi-
ents of a scientific in-kind grant from the now defunct
company uBiome, we collected stool samples. uBiome
comprehensively characterized the biogeography of the
human microbiome using high-throughput sequencing
of the microbial 16S rRNA gene and released all data to
UNC for analysis. After their company dissolved in Oct
2019, all processing transferred to the Carroll Lab at
UNC (I. Carroll, Director). In order to obtain high-
resolution taxonomic and functional microbiome data,
we will perform whole genome shotgun sequencing. Raw
sequence data will be quality filtered and trimmed to re-
move bases with Phred quality scores less than 20.
Downstream bioinformatics analysis will consist of: i)
taxonomic composition; ii) functional composition; iii)
alpha diversity (as measured by absolute numbers of se-
quence variants and the Shannon index of diversity) and
(quantified by Bray Curtis and UniFrac metrics); and iv)
computing descriptive statistics and identifying groups
within the data, as well as performing statistical analyses
between subgroups using additional metadata, where
available [39]. Since the sequencing technology and bio-
informatics tools are rapidly advancing, we will utilize
the most suitable methods and tools available at the time
of analysis.
Planned data analysis
Genomics and microbiota aims
We will combine BEGIN samples with other samples in
the PGC-ED for meta-analysis. We will conduct cross-
disorder analyses to identify loci that cut across diagnos-
tic categories by leveraging existing high-quality results
for anorexia nervosa, major depressive disorder, schizo-
phrenia, bipolar disorder, and other psychiatric and
metabolic phenotypes. We will use advanced methods
[40] to compute SNP heritabilities and genetic correla-
tions across psychiatric and metabolic traits. We will cal-
culate metabolic and psychiatric trait & disorder
polygenic scores (PGS) using PRSice, (http://www.prsice.
info). A leave-one-sample-out process will be carried out
to calculate BN/BED PGSs. The calculated PGS will be
the weighted numbers of risk alleles carried by each case
and control. This aim will illuminate, from a fundamen-
tal perspective, the genetic architecture of BN/BED and
its relation to other psychiatric disorders and metabolic
conditions.
We will compare taxonomic composition and diversity
of the gut microbiota for BEGIN participants, compare
BN with BED, and both to a reference control panel. We
will control for multiple covariates in all analyses (e.g.,
obesity).
We can now rapidly do GWAS on multiple pheno-
types – e.g., GWAS for 22 K transcriptomic, 8 K prote-
omic, or 1 K metabolomic measures. (1) We will adapt
and extend these methods to evaluate host genomic-
microbiota interactions by conducting ~ 15 K GWAS for
species-level microbial measures while controlling for
multiple comparisons. (2) We will generate microbiome
“modules”, clusters of species with high intra-group cor-
relations and low inter-group correlations. We will then
do a GWAS for these modules. (3) For all analyses, we
will pay particular attention to the genomic regions
highlighted in the prior literature (e.g., MHC, auto-
immunity, gut barrier, inflammatory bowel disease). (4)
We will utilize publicly available databases of summary
statistics across a range of psychiatric, personality, meta-
bolic, and physical activity phenotypes and employ both
trait-specific polygenic scores (PGS) and multi-polygenic
scores (MPS) to predict outcomes. We will use a novel
MPS approach developed by collaborator Breen and col-
leagues [41], that exploits genetic correlations between
the outcome trait and a multitude of traits by using the
joint predictive power of multiple polygenic scores in
one regression model. We will select relevant GWAS
from a centralized repository of summary statistics to
predict BN, BED, severity, treatment outcome. Using re-
peated cross-validation, we will train and validate the
prediction models using elastic net regularized regres-
sion, which is a multiple regression model suited to deal
with a large number of correlated predictors while pre-
venting overfitting [42]. We will then add microbiota
and phenotyping variables into the model to improve
predictive accuracy.
Digital longitudinal phenotyping aims
Our dynamic systems approach capitalizes on a combin-
ation of the passive and active data collection to address
all three of the longitudinal phenotyping aims. Each
stable state can be thought of as having homeostatic
properties that are reflected in associations between dif-
ferent levels of derivatives (i.e., change in value with re-
spect to time). For example, the relationship between
changes in heart rate from one moment to the next and
values of heart rate at the previous moment characterize
how heart rate fluctuates homeostatically about a “set
point.” This set point represents the heart rate value to
which the individual’s body returns when the person is
at rest [43]. Not only does this association characterize
the homeostatic heart rate value itself but also the rate
of return to the set point when a person’s heart rate is
perturbed (i.e., experiencing distress prior to a binge/
purge episode, physical load creating during exercise,
etc.). Higher order derivatives and accounting for more
variables simultaneously allows for testing more complex
homeostatic patterns (e.g., cycles), while including this
concept of rate of return to set point (i.e., systemic
stability).
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Aim 2 will be tested by first depicting the dynamics
that lead up to a binge or purge event in a multilevel
model. Aim 3 will be addressed by depicting the dynam-
ics once a binge or purge event has occurred. In this
case, analyses will focus on the 2 h after binge/purge
events (but not within an hour of a future event), again
modeling changes in heart rate and steps as a function
of current levels in heart rate and steps. Aim 4 will re-
quire depicting each instance in time in terms of risk for
being in one of the temporal states associated with sub-
sequent binge eating and/or purging. To do so, we will
utilize the posterior probabilities from a latent mixture
model where each pattern is differentiated by associa-
tions amongst different levels of change. Mixture model-
ing is a taxonomic approach where timepoints within
and between individuals can be grouped together as a
function of a model. In this case, the model will differen-
tiate groups of data as a function of the dynamic
properties.
To help ensure reproducibility, the sample will be split
in half with each half used as confirmation on the other
half generating competing models. Under large data cir-
cumstances such as these, rather than power, the pri-
mary concern is a combination of overfitting and
gaining a proper gauge of an effect. Generating compet-
ing models allows each of the samples to function as
confirmation of the other with the better fitting model
on both samples providing the more generalizable
solution.
Discussion
As a multi-pronged investigation, BEGIN will have
broad impact across various dimensions in the eating
disorders field. First, in the biological domain, BEGIN
will allow us to identify genetic and gut microbiota con-
tributors to disorder risk and maintenance and identify
genomic, enteric microbes, and behavioral predictors of
outcome. Second, in the behavioral domain, BEGIN will
allow us to build algorithms that predict behavioral
events (e.g., impending binges or purges) to enable real-
time intervention via wearable technology.
We intend this to be a transformative study in the field
of eating disorders. Through deep longitudinal pheno-
typing via the Apple Watch, we designed BEGIN to rap-
idly accelerate progress toward personalized precision
medicine for BN and BED. Advances in eating disorders
treatment have been slow and incremental. In our
Agency for Healthcare Quality and Research review of
treatments for BED [44], we noted that the evidence
base was challenged by small samples and single studies
introducing small variations on core therapeutic ap-
proaches with little or no additive efficacy. Wearable
sensors, such as the Apple Watch with the adapted Re-
covery Record app, offer us the opportunity to develop a
transformative improvement in BN and BED treatment.
BN and BED are model disorders with discrete and
measurable pathognomonic unhealthy behaviors. By ap-
plying dynamical systems models to the passive and ac-
tive data that we collect, we will bypass historical one-
size-fits-all CBT interventions for BN and BED and im-
mediately enter the era of personalized interventions for
eating disorders. Not only will we be able to build
models that predict binge and purge episodes within the
acute phase of the illness, but personalized extensions of
these models will allow us to identify and alert individ-
uals to impending slips and relapses after recovery.
Although traditional CBT interventions that rely on
in-session retrospective recall will never be entirely ob-
solete, we expect that the just-in-time approach afforded
by our dynamical systems models will render ours a cen-
tral feature in the future treatment of BN/BED. Results
from BEGIN will set the stage for subsequent studies in
which we will have achieved the ability to discriminate
across types of events (e.g., exercise, meal, binge, purge)
that will allow us to build in accurate push notifications
when an individual’s passive and active data signal an
impending binge or purge—truly tailoring treatment and
delivering it in-the-moment. Moreover, Recovery Record
already has a clinician interface, and we predict that we
will be able to incorporate our models into provider in-
terfaces such that clinicians will be able to view and
interact with the alerts that emerge, thus supporting the
provision of data-informed care.
Ultimately, we foresee that this study will advance
both cognitive-behavioral approaches to understanding
and treating eating disorders and dynamical systems the-
ory of behavior change to incorporate both intensive
longitudinal behavioral and physiological data. Although
our focus is on eating disorders, we intend our models
to be readily adaptable for other psychiatric (and som-
atic) conditions that have identifiable measurable indices
in order to usher us more rapidly toward individualized
interventions that attend to the psychology, the biology,
and the dynamic environment of the individual.
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